相关实验视频
Updated: Jul 1, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
乌帕达西提尼布与托法西提尼布治疗性结肠炎的一年比较有效性:一个多中心队列研究
Rahul S Dalal1, Govind Kallumkal2, Heidy J Cabral1
1Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
The American journal of gastroenterology
|March 12, 2024
概括
与tofacitinib相比,upadacitinib在52周内在治疗性结肠炎 (UC) 患者中实现无类固醇临床缓解方面表现出更高的有效性. 内镜检查结果显示,两种治疗方法之间没有显著差异.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 治疗性结肠炎 (UC) 的JAK抑制剂的比较有效性尚不清楚.
- 乌帕达西提尼布和托法西提尼布是常用的UC治疗方法.
- 了解不同治疗结果对于患者管理至关重要.
研究的目的:
- 为了比较upadacitinib与tofacitinib在实现UC患者临床和内镜缓解方面的疗效.
- 为了评估无类固醇临床缓解 (SFCR) 和内镜反应/缓解在52周.
- 提供关于这些JAK抑制剂的比较有效性的真实世界的证据.
主要方法:
- 追溯队列研究设计.
- 包括成人患者开始使用upadacitinib或tofacitinib治疗UC.
- 用治疗加权后勤回归的利用逆概率进行分析.
- 在52周评估无类固醇临床缓解 (SFCR) 和内镜反应/缓解.
主要成果:
- 包括155名患者:81名患者接受上巴西提尼布,74名患者接受托法西提尼布.
- 与托法西替尼相比,乌帕达西替尼的SFCR (OR3.01,95%CI1.39-6.55) 的几率显著更高.
- 两组之间没有观察到内镜反应或缓解率的显著差异.
结论:
- 在52周的UC患者中,upadacitinib在实现无类固醇临床缓解方面比tofacitinib更有效.
- 内镜结局在上达西提尼布和托法西提尼布之间没有显著差异.
- 研究结果支持upadacitinib作为一种潜在的更有效的选择,可以在UC中实现临床缓解.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163

